Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Friday, October 2, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Daiichi Sankyo and AstraZeneca have formed a clinical trial collaboration with Summit Therapeutics to assess the efficacy of Datroway® in combination with ivonescimab across various tumor types, including lung and breast cancers. The collaboration will commence with a phase 3 trial focusing on first-line treatment for triple negative breast cancer. This partnership aims to enhance treatment options for patients with these cancers.
Market Sentiment Analysis
POSITIVE FACTORS
Collaboration between Daiichi Sankyo and AstraZeneca is promising.
Evaluation of Datroway® in combination with ivonescimab targets multiple tumor types.
Phase 3 trial initiation in triple negative breast cancer is a significant step.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
1.5%
average across 15 past catalysts
Lead asset
Elecoglipron
Phase 3 · Chronic Kidney Disease
Full Press Release Details
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC). Datroway is a specifically engineered TROP2 directed DXd antibo
Frequently Asked Questions
What is the purpose of the collaboration?
The collaboration aims to evaluate Datroway® in combination with ivonescimab across multiple tumor types.
Which tumor types are being targeted?
The trial will focus on lung and breast cancers, particularly triple negative breast cancer.
What phase is the trial starting with?
The collaboration will begin with a phase 3 trial.
Who are the companies involved in the collaboration?
The collaboration involves Daiichi Sankyo, AstraZeneca, and Summit Therapeutics.